CRN Greater Manchester named Sanofi first UK Premier Site
Global pharmaceutical company Sanofi has entered into a landmark clinical research partnership with Greater Manchester.
NIHR Clinical Research Network (CRN) Greater Manchester has been named Sanofi’s first UK Premier Site.
The collaboration will assist both organisations’ aim to accelerate Research and Development to address the medical need of patients.
Premier Site status creates a mutually beneficial environment; closely linking cutting-edge clinical trials sponsored by Sanofi with CRN Greater Manchester’s network of R&D experts and suite of primary and secondary research centres.
It is the latest in a succession of partnerships which Sanofi enjoys with a range of partners in the health system.
CRN Greater Manchester supports the delivery of health research across a population of almost three million people, working with 14 NHS trusts and 11 Clinical Commissioning Groups (incorporating more than 500 GP practices).
The relationship will:
- Help research institutions improve patient recruitment rates. This will drive efficiencies along the research pathway and reduce costs.
- Provide greater opportunities for sites to participate in Sanofi studies.
- Provide Principle Investigators and their staff with opportunities to shape protocol designs in the concept stages of clinical trials.
- Increase researchers’ visibility into Sanofi’s portfolio of clinical trials to facilitate PI and institution input into planning.
Sarah Fallon, CRN Greater Manchester Life-Sciences Industry Delivery Lead, said: “We are delighted to have been chosen as Sanofi’s first UK Premier Site and are excited by the opportunities this closer working relationship offers our network and, most importantly, patient care.
“Our CRN has a wealth of talented individuals working in research across primary and secondary care, along with an enviable clinical research infrastructure that allows us to recruit and innovate at centres throughout a socially and economically diverse region.
Premier Site status with Sanofi will allow us even better opportunities to maximise our expertise and resources and improve patient access to clinical studies at centres around Greater Manchester.
Mital Desai, Clinical Studies Unit Country Head, UK & Ireland Clinical Studies Unit, Sanofi, said: “Premier Site status is truly a mutually beneficial relationship for Sanofi and CRN GM.
The working relationship will boost R&D efficiencies in start-up, recruitment, and data quality but ultimately we aim to ensure the patient is the real benefactor, by accelerating the introduction of new therapies.